CRD007 for the Treatment of Abdominal Aorta Aneurysm (The AORTA Trial)

RSPR Pharma

Status and phase: Completed; Phase 2

Conditions: Abdominal Aortic Aneurysm

Treatments: Drug: CRD007 matching placebo; Drug: CRD007

Study type: Interventional

Funder types: Industry

Identifiers

NCT01354184

Cardoz-003

Details and patient eligibility

About

This is an investigation of the efficacy and safety of CRD007 compared to placebo in the treatment of patients with abdominal aortic aneurysm.

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Infra-renal abdominal aortic aneurysm

Exclusion criteria

• Previous infra-renal aortic surgery
• Known diabetes

Trial design

0 participants in 4 patient groups, including a placebo group

CRD007 10 mg tablet

Experimental group

Treatment:

Drug: CRD007

CRD007 25 mg tablet

Experimental group

Treatment:

Drug: CRD007

CRD007 40 mg tablet

Experimental group

Treatment:

Drug: CRD007

CRD007 matching placebo tablet

Placebo Comparator group

Treatment:

Drug: CRD007 matching placebo